TY - JOUR
T1 - In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae
AU - Patel, Robin
AU - Rouse, Mark S.
AU - Piper, Kerryl E.
AU - Cockerill, Franklin R.
AU - Steckelberg, James M.
PY - 1998/2
Y1 - 1998/2
N2 - We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistsant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.
AB - We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistsant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.
UR - http://www.scopus.com/inward/record.url?scp=0031890133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031890133&partnerID=8YFLogxK
U2 - 10.1016/S0732-8893(97)00207-1
DO - 10.1016/S0732-8893(97)00207-1
M3 - Article
C2 - 9554174
AN - SCOPUS:0031890133
SN - 0732-8893
VL - 30
SP - 89
EP - 92
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
ER -